IPG Photonics Corp banner

IPG Photonics Corp
F:IPF

Watchlist Manager
IPG Photonics Corp Logo
IPG Photonics Corp
F:IPF
Watchlist
Price: 66.88 EUR 0.87%
Market Cap: €3B

IPG Photonics Corp
Investor Relations

IPG Photonics makes fiber lasers and laser-based systems used to cut, weld, mark, clean, and process materials in factories. Its products are sold to manufacturers that need precise, high-power tools for metalworking and other industrial jobs, including customers in automotive, electronics, medical device, and aerospace supply chains. The company earns money mainly by selling laser sources, complete laser systems, and related components and service. These products are usually bought by equipment makers or end users that install them on production lines, so IPG sits in the middle of the industrial manufacturing process rather than selling to consumers. What makes IPG different is that it is not just a parts seller. It designs and makes many of the core parts of its laser technology itself, which gives it tighter control over performance, reliability, and cost. It also works closely with customers to match lasers to specific manufacturing tasks, which makes its business tied to factory productivity and precision work.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Aug 4, 2026
AI Summary
Q2 2026

Revenue: IPG Photonics said second-quarter revenue was $279 million, up 11% year over year and above the midpoint of guidance, with both Industrial Solutions and Advanced Solutions growing sequentially.

Margins: Adjusted gross margin came in above the top end of guidance at 40.7%, helped by about $4.7 million of tariff refunds, while adjusted EPS was also above expectations at $0.58.

Demand: Management said bookings improved, book-to-bill stayed above 1 for the third straight quarter, and demand remained strong across industrial, medical, semiconductor and defense end markets.

Strategy: The company highlighted progress in battery welding, additive manufacturing, and semiconductor applications, while also emphasizing a move up the value chain into higher-margin systems and subsystems.

Deal: IPG announced a binding offer to buy Lumibird Medical, saying the deal should expand its medical platform, improve business mix, and be accretive to gross margin, EBITDA and adjusted EPS in the first year.

Outlook: Third-quarter guidance calls for revenue of $265 million to $295 million and adjusted EPS of $0.30 to $0.60, with tariffs expected to weigh on gross margin by about 150 basis points.

Defense: The company began shipping Lockheed Martin’s CROSSBOW order and said it remains optimistic about broader directed-energy demand, though the opportunity is still early.

Key Financials
Revenue
$279 million
Industrial Solutions revenue
up 16% year over year
Advanced Solutions revenue
down 9% year over year
Emerging growth products as a share of revenue
58%
North America revenue
down 2% year over year
Europe revenue
up 5% year over year
Asia revenue
up 19% year over year
Gross margin
40.4%
Adjusted gross margin
40.7%
Tariff refund benefit
$4.7 million
Adjusted operating expenses
$91 million
Operating income
$5 million
Net income
$5 million
Earnings per diluted share
$0.12
Adjusted earnings per diluted share
$0.58
Adjusted EBITDA
$49 million
Cash, cash equivalents and short-term investments
$871 million
Long-term investments
$33 million
Cash flow from operations
$38 million
Capital expenditures
$21 million
Year-to-date capital expenditures
$37 million
Medical business size
about 7% to 8% of revenue
CROSSBOW order shipments
began shipping Lockheed Martin’s order this quarter
Earnings Call Recording
Other Earnings Calls

Management

Mr. Timothy P. V. Mammen
Senior VP & CFO
No Bio Available
Mr. Angelo P. Lopresti II
Senior VP, General Counsel & Secretary
No Bio Available
Mr. Trevor D. Ness
Senior Vice President of Sales & Strategic Business Development
No Bio Available
Dr. Eugene A. Scherbakov Ph.D.
Director & Advisor
No Bio Available
Dr. Mark Milton Gitin
CEO & Director
No Bio Available
Mr. Thomas J. Burgomaster
VP, Corporate Controller, Treasurer & Chief Accounting Officer
No Bio Available
Dr. Igor Samartsev Ph.D.
Senior VP & Chief Scientist
No Bio Available
Mr. Eugene Fedotoff
Senior Director of Investor Relations
No Bio Available
John Weaver
Vice President of Human Resources Worldwide
No Bio Available

Contacts

Address
MASSACHUSETTS
Marlborough
377 Simarano Drive
Contacts